Proteoglycans and WT1 as markers for distinguishing adenocarcinoma, epithelioid mesothelioma, and benign mesothelium
Authors:
- 3 February 2003
- journal article
- research article
- Published by Wiley in The Journal of Pathology
- Vol. 199 (4) , 479-487
Abstract
Malignant mesothelioma is a tumour frequently accompanied by an effusion with elevated hyaluronan levels. To distinguish malignant mesothelioma, adenocarcinoma, and reactive benign mesothelium with cytological and histological methods including immunocytochemistry is a major diagnostic challenge. The Wilms' tumour susceptibility gene 1 (WT1), expressed during transition of mesenchyme to epithelial tissues, is regarded as a marker for the mesothelial lineage. Its effect on the cell phenotype may be regulated via the syndecans, i.e. proteoglycans on the cell surface. To determine how WT1, proteoglycans, and hyaluronan synthase are expressed in mesothelioma, adenocarcinoma, and reactive benign mesothelium, we studied these molecules at the mRNA and protein levels, with the additional purpose of finding diagnostic parameters. Adenocarcinoma cells produced more mRNA for syndecan‐1, but cells derived from mesothelium expressed WT1, biglycan, and larger amounts of syndecan‐2. The difference in gene expression of these two syndecans was best monitored by the ratio between them. Syndecan‐4 was highly expressed in all malignant cell lines, this expression being 1.7–5 times greater than in benign mesothelial cells. Although hyaluronan synthase‐1 and versican could not distinguish between the three conditions, versican expression was associated with a high rate of proliferation. These findings suggest that syndecan‐1 and syndecan‐2 together may be useful diagnostic markers, with stronger staining for the latter epitope in mesothelial tissues. The alternating appearance of these two syndecans can be shown not only by RT‐PCR and FACS in vitro, but also by immunohistochemistry on clinical material. Copyright © 2003 John Wiley & Sons, Ltd.Keywords
Funding Information
- Swedish Cancer Fund (2485)
- Swedish Heart and Lung Fund
This publication has 28 references indexed in Scilit:
- Syndecan‐4 up‐regulation in proliferative renal disease is related to microfilament organizationThe FASEB Journal, 2001
- Delayed wound repair and impaired angiogenesis in mice lacking syndecan-4Journal of Clinical Investigation, 2001
- An Optimized Battery of Eight Antibodies That Can Distinguish Most Cases of Epithelial Mesothelioma From AdenocarcinomaAmerican Journal of Clinical Pathology, 2000
- Differentiation of Mesothelioma Cells Is Influenced by the Expression of ProteoglycansExperimental Cell Research, 2000
- Expression of genes coding for proteoglycans and Wilms' tumour susceptibility gene 1 (WT1) by variously differentiated benign human mesothelial cellsDifferentiation, 1999
- Expression of the Wilms' Tumor Gene WT1 in Solid Tumors and Its Involvement in Tumor Cell GrowthJapanese Journal of Cancer Research, 1999
- Syndecan-1 expression in malignant mesothelioma: correlation with cell differentiation, WT1 expression, and clinical outcomeThe Journal of Pathology, 1998
- The Wilms tumour gene WT1 is expressed in murine mesoderm–derived tissues and mutated in a human mesotheliomaNature Genetics, 1993
- Tissue, Developmental, and Tumor-Specific Expression of Divergent Transcripts in Wilms TumorScience, 1990
- Expression and localization of the two small proteoglycans biglycan and decorin in developing human skeletal and non-skeletal tissues.Journal of Histochemistry & Cytochemistry, 1990